Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said ...

Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for obese Australians without ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Conversely, Eduardo Grunvald, MD, medical director of the weight management program at UC San Diego Health, sees less of an issue as long as there is a legitimate prescriber. Some of his patients have ...

Eli Lilly says new research shows its medication ... in Spain that shows significant potential for weight loss that comes in pill form. A new study finds the drug semaglutide appears to lower ...

Eli Lilly expects to have data from a late-stage trial involving orforglipron by April. This weight loss pill helped patients lose nearly 15% of their weight in a phase 2 trial. Lilly has been a ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...